A LinkedIn post from Xeltis indicates that the company’s team plans to attend the Charing Cross (CX) Symposium in London, described in the post as a leading global vascular and endovascular meeting. The post highlights two podium presentations by key opinion leaders featuring new 12‑month multicenter EU pivotal trial data for Xeltis’ aXess vascular access conduit.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
According to the post, Dr. Augusto Ministro is expected to present 12‑month results from the aXess study in a session on the science behind clinical practice, while Prof. Frans Moll is scheduled to discuss a next‑generation bioabsorbable conduit for bypass in a peripheral innovation session. The presence of high‑profile vascular surgeons as presenters may help validate Xeltis’ technology in the clinical community and could support future adoption if the data are viewed favorably.
The post also lists a broad on‑site delegation from Xeltis, including the CEO, CMO, and senior leaders in clinical operations, commercial functions, and strategic marketing, as well as a dedicated company booth. This visible commitment to medical‑conference engagement suggests an emphasis on building clinical evidence, strengthening relationships with vascular specialists, and preparing for potential commercialization pathways in dialysis and vascular access markets.
For investors, the forthcoming 12‑month pivotal trial data for aXess appear to be a key near‑term catalyst, though the LinkedIn content does not disclose any clinical outcomes or regulatory milestones. If subsequent public data releases indicate strong safety and efficacy, Xeltis could enhance its position in the vascular access segment, potentially expanding its addressable market in dialysis care and improving its long‑term growth prospects.